CHA Vaccine Research Institute

CHA Vaccine Research Institute has a debt-to-equity ratio of 0.75 and a current ratio of 1.66, indicating moderate liquidity and manageable short-term obligations. However, the company reported negative operating cash flow of -11,017,064,870 KRW and free cash flow of -15,744,776,160 KRW, signaling significant cash outflows from operations. The negative net income of -16,044,489,540 KRW and operating income of -14,472,084,990 KRW highlight the company's current unprofitability. Return on equity of -1.35 and return on assets of -0.54 further underscore the poor performance relative to equity and asset utilization. The company's profitability metrics fall significantly below the industry median for return on equity and return on assets, which are typically positive for firms in the Biotechnology & Medical Research industry. Gross profit of 143,918,220 KRW is minimal compared to the company's total assets of 29,781,550,830 KRW, indicating that the company is not generating sufficient revenue to cover its costs. The negative operating income and net income suggest that the company is not yet at a stage where it can sustain profitability from its core operations. CHA Vaccine Research Institute's revenue is concentrated in its core business of vaccine and immunotherapy research, with no disclosed geographic diversification in the provided data. The company's business model is heavily R&D-driven, with a focus on developing premium preventive vaccines and therapeutic vaccines. The lack of geographic diversification and the high R&D intensity suggest that the company is vulnerable to market-specific risks and regulatory changes in its primary operating region. The company's outlook for the current fiscal year is negative, with no significant revenue growth expected. The operating cash flow and free cash flow are expected to remain negative, reflecting ongoing investment in R&D and limited commercialization of products. The capital expenditure of -155,920,620 KRW indicates continued investment in infrastructure and research capabilities. The company's long-term debt of 8,840,880,560 KRW and total liabilities of 17,922,501,080 KRW suggest that the company is leveraging debt to fund its operations and growth. The risk assessment indicates a medium liquidity risk due to the company's negative net cash position after subtracting total debt. The dilution risk is currently low, with no significant dilution expected in the near term. However, the company's negative operating and free cash flows suggest that it may need to raise additional capital in the future, which could lead to dilution. The company's reliance on R&D and the absence of commercialized products increase the risk of failure to achieve profitability. Recent filings and transcripts indicate that the company is focused on advancing its vaccine pipeline and securing partnerships for distribution and licensing. The company has not disclosed any major regulatory or legal challenges in the provided data. The company's strategy appears to be centered on long-term R&D investment and product development, with the expectation that commercialization will occur in the future.